Showing 7761-7770 of 10904 results for "".
Various Benefits of Aryl Hydrocarbon Receptor Agonists
https://practicaldermatology.com/videos/dermatology-dialogues-aryl-hydrocarbon-receptor-agonism/various-benefits-of-aryl-hydrocarbon-receptor-agonists/70708/In the fourth installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, discuss how topical therapies can be used to control inflammation and how to talk about that with patients.Mechanism of Action for Aryl Hydrocarbon Receptor Agonists
https://practicaldermatology.com/videos/dermatology-dialogues-aryl-hydrocarbon-receptor-agonism/mechanism-of-action-for-aryl-hydrocarbon-receptor-agonists/70705/In the first installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, discuss the aryl hydrocarbon receptor (AhR) pathway and how AhR agonists work.Tapinarof’s Place in Inflammatory Disease Treatment
https://practicaldermatology.com/videos/dermatology-dialogues-aryl-hydrocarbon-receptor-agonism/tapinarofs-place-in-inflammatory-disease-treatment/70706/In the second installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, explain how tapinarof fits in the armamentarium for treating inflammatory dermatoses.The Treatment Landscape for Children and Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37153/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, provides an overview of current therapeutic options for pediatric atopic dermatitis patients.Practical Dermatology Roundtable: Reclaiming Urticaria, Ch. 4
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-reclaiming-urticaria-ch-4/84989/In the fourth installment of this five-part series, Brad P. Glick, DO, MPH, FAAD; Laura K. Ferris, MD, PhD; and Lawrence J. Green, MD, FAAD, discuss the quality-of-life burden of CSU, practical antihistamine escalation, and how to choose among injectable and oral targeted therapies.Using Topical Therapies for Pediatric Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology/program-name/70392/In the second installment of this five-part series, Naiem T. Issa, MD, PhD, FAAD, and Maureen N. Offiah, MD, FAAD, explore special considerations when using topical therapies for pediatric patients with atopic dermatitis.Updates on Psoriasis Biologics
https://practicaldermatology.com/programs/practical-dermatology/updates-on-psoriasis-biologics/35894/Jashin J. Wu, MD, discusses biologics for psoriasis, including a meta-analyses of best biologics for different types of the condition, at Music City SCALE 2025.Cutaneous Toxicities in Graft-versus-host Disease
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/cutaneous-toxicities-in-graft-versus-host-disease/33013/Meghan Heberton, MD, an assistant professor of dermatology at UT Southwestern Medical Center, talks about her presentation at Masterclasses in Dermatology on the latest updates on cutaneous toxicities in Graft-versus-host (GvHD) disease.Noah Worcester 2024: Dr. Cohen on Lasers
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-cohen-lasers/24578/Joel L. Cohen, MD, FAAD, summarizes his lecture on laser resurfacing and perioral rejuvenation at the 2024 Noah Worcester Dermatological Society meeting.Choosing the Right Resurfacing Treatment
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/choosing-the-right-resurfacing-treatment/20141/Joel L. Cohen, MD discusses how he assesses the area around the mouth to determine the best resurfacing treatment option. From fine lines and etching around the mouth to issues with pigmentation and redness, he says there are many options from low-downtime treatments to full-field erbium treatments.